UNSPSC 51401553: Temazepam

This classification denotes an anti-anxiety agent, gaba modulator, hypnotic, and sedative with the molecular formula C16H13ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CHB1QD2QSS, chemically known as 1,3-dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2h-1,4-benzodiazepin-2-one but generally known as temazepam, which bears US NIH Compound Identifier 5391. European Medicines Agency schedules Temazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10880MIG.

UNSPSC 51401553 Temazepam is a Commodity code that nominally identifies a specific controlled pharmaceutical product, but recent state and local solicitations tagged to this code show little activity directly aligned with temazepam procurement. Instead, the code appears in opportunities that address broader pharmaceutical supply and opioid-response initiatives. State and local governments issuing under this code seek to procure controlled and over-the-counter pharmaceuticals, naloxone and drug deactivation systems for community health and opioid-intervention programs, and generic multi-source pharmaceuticals through cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local facilities across participating jurisdictions including Oregon). The scope reflects a mix of emergency-response pharmaceutical procurement and routine generic drug supply contracting for government health programs.

Recent opportunities span Florida, Texas, and Minnesota-led cooperative purchasing with regional reach. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, with a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local facilities, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. These opportunities emphasize fixed-price and competitive bidding models, compliance with FDA and Drug Supply Chain Security Act requirements, and performance through established pharmaceutical distribution channels.